Clinical trials: Hepatitis C Virus (HCV)
Chronic Hepatitis C
Efficacy and Safety of Danoprevir/r + PR 12-week Triple Therapy in Treatment-Naive, Non-Cirrhotic, G1 CHC China II
The purpose of this study is to evaluate the Efficacy, Safety and Pharmacokinetics of Ritonavir-boosted Danoprevir (ASC08) in Combination with Peg-IFN and RBV in Treatment-Naive Non-Cirrhotic Patients Who Have Chronic Hepatitis…
- Trial name
- NCT03020004
- Testing
- Danoprevir, Ritonavir, peginterferon alfa-2a
- Volunteers
- 70 people
- Sponsor
- Ascletis Pharmaceuticals Co., Ltd.
Hepatitis C
Prevalence of Hepatitis c Virus Infection Among Rheumatological Patients
Egypt has the highest prevalence of hepatitis C virus (HCV) in the world. In 2015, the prevalence of HCV RNA was found to be 7.0%.(1) The prevalence of HCV was studied in Rheumatoid arthritis in few studies(2,3), but to our…
- Trial name
- NCT03587714
- Testing
- HCV RT-PCR
- Where
- Egypt
- Volunteers
- 800 people
- Sponsor
- Assiut University
HIV, Hepatitis B, Hepatitis C and Syphilis Infections
Counseling and Reminders for Regular HIV and STIs Screening
Counseling intervention: Primary objective: to evaluate and compare, in at-risk populations, the efficacy of three different counseling methods in terms of propensity to come back for a HIV re-test.
- Trial name
- Napneung-1 (NCT02752152)
- Testing
- Computer-assisted counseling, On-demand counseling, Standard counseling
- Where
- 3 sites in Thailand
- Volunteers
- 1,961 people, healthy volunteers welcome
- Sponsor
- Institut de Recherche pour le Developpement
Hepatitis C, Chronic
A Study of TMC435 in Participants With Genotype 1 Hepatitis C Virus (HCV) Infection
The purpose of this study is to evaluate the efficacy and safety of TMC435 in combination with peginterferon alfa-2b and ribavirin in chronic genotype 1 hepatitis C virus (HCV)-infected participants who are treatment-naive or…
- Trial name
- NCT01366638
- Testing
- TMC435, Peginterferon alfa-2b (pegIFN alfa-2b), Ribavirin (RBV)
- Where
- 11 sites in Japan
- Volunteers
- 79 people
- Sponsor
- Janssen Pharmaceutical K.K.
Hepatitis C
Study of the Immune Response to Hepatitis C Virus
The purpose of this study is to investigate the mechanism of a successful immune response to hepatitis C virus (HCV) infection. Currently, it is believed that the immune system is involved in responding to HCV infection, but how…
- Trial name
- NCT00237432
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Rockefeller University
Hepatitis C, Chronic
Effect of Infliximab on the Efficacy of Peg-Intron/Ribavirin in Patients With Hepatitis C (Study P04257AM4)(COMPLETED)
This is a Phase IIIB, randomized, prospective, multicenter, single-country, open-label, controlled pilot trial designed to evaluate the effect of infliximab induction therapy on sustained virologic response (SVR) to treatment…
- Trial name
- Pegade (NCT00237484)
- Testing
- Induction dose of (a) infliximab followed by combination of (b) pegylated interferon alfa-2b and (c) ribavirin, Combination of (a) pegylated interferon alfa-2b and (b) ribavirin
- Volunteers
- 89 people
- Sponsor
- Merck Sharp & Dohme LLC
Hepacivirus, Pregnancy
Observational Study of the Interaction Between Hepatitis C Virus Infection and Pregnancy
The goal of this observational study is to learn about he effects of hepatitis C virus on pregnancy. The main question[s] it aims to answer are: Effect of hepatitis C virus on liver function in pregnant women Mother-to-child…
- Trial name
- NCT05929963
- Testing
- HCV infection status
- Where
- China
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Beijing Ditan Hospital
Hepatitis, Chronic Active
CPG10101 Combination Therapy For The Treatment Of Hepatitis C In Non-Responder (Null And Partial Responder) Hepatitis C Virus (HCV) Genotype 1 Infected Subjects
The purpose of this study is to determine the efficacy and tolerability of CPG 10101 at two different dose levels with pegylated-interferon-alpha 2B (PEG-IFN) plus ribavirin (RBV) compared to PEG-IFN and RBV without CPG 10101 in…
- Trial name
- NCT00277238
- Testing
- CPG10101, Control
- Where
- 14 sites in United States
- Volunteers
- 113 people
- Sponsor
- Pfizer
HIV Infections, Hepatitis C
Interaction of Alcohol and Highly Active Antiretroviral Therapy (HAART) in HIV/AIDS and HIV/AIDS With Hepatitis C Virus (HCV) Co-Infection
The proposed studies will examine the extent of pharmacokinetic and pharmacodynamic interactions between alcohol and various antiretroviral therapies in those with HIV/AIDS, HIV/HCV co-infection, mild HCV and healthy subjects.
- Trial name
- NCT00879047
- Testing
- Alcohol
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Hepatitis C
TeleHepC Treatment Trial
The main goal of this study is to test the efficacy of a peer-facilitated telemedicine HCV treatment implementation strategy for people who use drugs versus local HCV treatment referral for achieving HCV sustained viral response…
- Trial name
- NCT04798521
- Testing
- Tele-HCV, Community Linkage to Care
- Where
- 3 sites in United States
- Volunteers
- 203 people
- Sponsor
- Oregon Health and Science University
Chronic Hepatitis C
Hepatitis C Treatment Naive Genotype 1 Consensus Interferon Trial
Data have suggested that consensus interferon (CIFN) has greater antiviral activity in vitro compared with interferon alfa-2a or alfa-2b.
- Trial name
- NCT00211692
- Testing
- consensus interferon (Interferon Alfacon-1) and ribavirin, Consensus Interferon alfa (CIFN) and ribavirin
- Volunteers
- 64 people
- Sponsor
- Minneapolis Veterans Affairs Medical Center
HIV-1-infection, Hepatitis C, Chronic
Switch to Genvoya Followed by HCV Therapy With Epclusa Followed by Simplification of HIV Therapy With Biktarvy in Patients With HIV-HCV Co-Infected Subjects on Opioid Substitution Therapy
The study hypothesis is to determine the feasibility of switching HIV-HCV co-infected patients receiving methadone or buprenorphine/naloxone as opioid substitution therapy with suppressed HIV RNA viral load on current…
- Conditions
- HIV-1-infection, Hepatitis C, Chronic, Methadone Dependence, Opioid Dependence
- Trial name
- NCT03549312
- Testing
- Genvoya, Epclusa, Biktarvy
- Where
- Canada
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Saskatchewan Health Authority - Regina Area
Hepatitis C, Chronic, HIV CDC Category A1
A Study of the Safety and Effectiveness of Simeprevir and Sofosbuvir for Patients With HIV and Hepatitis C
This is a study of the safety and effectiveness of the hepatitis C medications sofosbuvir and simeprevir in patients who have both the HIV and hepatitis C (HCV) viruses.
- Trial name
- NCT02206932
- Testing
- Sofosbuvir + Simeprevir
- Where
- United States
- Sponsor
- University of California, San Francisco
Hepatitis C, Hepatitis B
Study to Evaluate the Prevalence of Hepatitis C in Spain in 2015 (PREVHEP)
The hypothesis of this investigation stresses that the current understanding of the prevalence of HCV infection in the general population and in different subgroups will serve to lay out medium- and long-term measures for action…
- Trial name
- PREVHEP (NCT02749864)
- Where
- 3 sites in Spain
- Volunteers
- 12,246 people
- Sponsor
- Instituto de Investigación Marqués de Valdecilla
Hepatitis C, Pregnancy Complications
Transmission of Chronic Hepatitis C in Pregnancy
This is a multicenter, non-comparative, observational study that will recruit women with singleton pregnancy and chronic HCV infection to determine the natural history of chronic HCV in pregnancy and the rate of vertical…
- Conditions
- Hepatitis C, Pregnancy Complications, Vertical Disease Transmission
- Trial name
- NCT03570112
- Testing
- SOF/VEL- sofosbuvir 400mg and velpatasvir 100mg
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- The Christ Hospital
Liver Cancer, Hepatitis B
Viral & Host Factors Associated With Hepatitis B Virus-related Hepatocellular Carcinoma
Adult liver cancer is the third leading cause of cancer deaths worldwide. The major risk factor for liver cancer is hepatitis B virus (HBV) infection.
- Conditions
- Liver Cancer, Hepatitis B, Hepatitis C, Hepatobiliary Cancers Liver
- Trial name
- NCT00767936
- Where
- United States
- Volunteers
- 135 people
- Sponsor
- Stanford University
Hepatitis C Virus Infection
Efficacy and Safety Study of Simeprevir in Combination With Sofosbuvir in Participants With Genotype 1 Chronic Hepatitis C Virus Infection and Cirrhosis
The purpose of the study is to investigate the efficacy and safety of 12 weeks of simeprevir (150 mg qd) in combination with sofosbuvir (400 mg qd) in chronic hepatitis C virus (HCV) genotype 1 infected men and women with…
- Trial name
- NCT02114151
- Testing
- Simeprevir, Sofosbuvir
- Where
- 34 sites in United States, Canada
- Volunteers
- 103 people
- Sponsor
- Janssen Infectious Diseases BVBA
HCV Infection
Safety, Tolerability, and Antiviral Activity of 24 or 48 Weeks of GS-9190 in Combination With Peginterferon Alfa 2a and Ribavirin for the Treatment of Genotype-1 Chronic HCV Infection
The purpose of this study is to compare the safety, tolerability and effectiveness of the experimental drug GS-9190 when administered for 24 or 48 weeks with peginterferon alfa 2a and ribavirin for the treatment of genotype-1…
- Trial name
- NCT00743795
- Testing
- GS-9190, Peginterferon Alfa 2a, Ribavirin
- Where
- 72 sites in United States, Belgium and 5 more
- Volunteers
- 252 people
- Sponsor
- Gilead Sciences
Hepatitis C Virus (HCV)
Safety and Efficacy Study of Pegylated Interferon Lambda Versus Pegylated Interferon Alfa, Plus Ribavirin in Subjects With Hepatitis C
The purpose of this study is to determine if 48 weeks of therapy with Pegylated Interferon Lambda plus Ribavirin is effective and safe for a treatment of chronic hepatitis C (CHC) compared to therapy with Pegylated Interferon…
- Trial name
- NCT01447394
- Testing
- Pegylated Interferon Lambda, Pegylated Interferon Alfa-2a, Ribavirin
- Where
- 100 sites in United States, Canada and 18 more
- Sponsor
- Bristol-Myers Squibb
HIV, Hepatitis C
Impact of an Antibiotic (Rifaximin) on Liver Scarring in HIV-Infected Patients With Liver Disease
For HIV-infected patients who have access to treatment, liver diseases are a major cause of morbidity and mortality. Hepatitis C is the most frequently encountered liver condition in this population.
- Trial name
- NCT01654939
- Testing
- Rifaximin
- Sponsor
- Douglas T. Dieterich
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.